Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
The intracerebroventricular (icv) application of streptozotocin (STZ) in low dosage was used in 3‐month‐old rats to explore brain insulin system dysfunction. Three months following STZ icv treatment, the expression of insulin‐1 and ‐2 mRNA was significantly reduced to 11% in hippocampus and to 28% in frontoparietal cerebral cortex, respectively. Insulin receptor (IR) mRNA expression decreased significantly in frontoparietal cerebral cortex and hippocampus (16% and 33% of control). At the protein/activity level, different abnormalities of protein tyrosine kinase activity (increase in hippocampus), total IR β‐subunit (decrease in hypothalamus) and phosphorylated IR tyrosine residues (increase) became apparent. The STZ‐induced disturbance in learning and memory capacities was not abolished by icv application of glucose transport inhibitors known to prevent STZ‐induced diabetes mellitus. The discrepancy between reduced IR gene expression and increase in both phosphorylated IR tyrosine residues/protein tyrosine kinase activity may indicate imbalance between phosphorylation/dephosphorylation of the IR β‐subunit causing its dysfunction. These abnormalities may point to a complex brain insulin system dysfunction after STZ icv application, which may lead to an increase in hyperphosphorylated tau‐protein concentration. Brain insulin system dysfunction is discussed as possible pathological core in the generation of hyperphosphorylated tau protein as a morphological marker of sporadic Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
Szkudelski, T. (2001) · Physiological Research · doi:10.33549/physiolres.930111 · Cited by 2,876
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Interestingly, in post-mortem aged control subjects, insulin gene expression was also highest in the hippocampus (Steen et al. 2005).”
BackgroundChangeux, J.-P., & Danchin, A. (1976) · Nature · doi:10.1038/264705a0 · Cited by 1,448
Jitsukawa, K., Sueki, H., Sato, S., & Anzai, T. (1987) · The American Journal of Dermatopathology · doi:10.1097/00000372-198704000-00003 · Cited by 1,131
Insulin in the Brain: A Hormonal Regulator of Energy Balance*
SCHWARTZ, M. W., FIGLEWICZ, D. P., BASKIN, D. G., WOODS, S. C., & PORTE, D. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-3-387 · Cited by 807
Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748 · cited 2×
“…glucose metabolism and its control by the neuronal insulin signal transduction system have been found in sporadic Alzheimer’s disease (SAD) (Hoyer et al. 1991; Frölich et al. 1998; Hoyer 2002, 2004), putting forward the hypothesis that SAD is the brain type of diabetes mellitus II (Hoyer 1998).”
BackgroundSelf-citationRole for neuronal insulin resistance in neurodegenerative diseases
Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308724101 · Cited by 637
Noble, E. P., Wurtman, R. J., & Axelrod, J. (1967) · Life Sciences · doi:10.1016/0024-3205(67)90157-9 · Cited by 561
Cited by
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y., Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 502
Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Goyal, S. N., Reddy, N. M., Patil, K. R., Nakhate, K. T., Ojha, S., Patil, C. R., & Agrawal, Y. O. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.11.032 · Cited by 419
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Grieb, P. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9132-3 · Cited by 361
Javed, H., Khan, M. M., Ahmad, A., Vaibhav, K., Ahmad, M. E., Khan, A., Ashafaq, M., Islam, F., Siddiqui, M. S., Safhi, M. M., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.046 · Cited by 357
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
“It has been proposed that oxidative stress and insulin resistance can lead independently to the accumulation of β-amyloid and tau protein [103,104], thus implying a strong correlation with AD pathology.”
BackgroundType 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313
Chen, Y., Liang, Z., Blanchard, J., Dai, C.-L., Sun, S., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Liu, F., & Gong, C.-X. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8375-5 · Cited by 288
Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease
Akhtar, A., & Sah, S. P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104707 · Cited by 279
Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272
Self-citationThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“Experimental animals in which brain insulin receptor expression and function are suppressed exhibit cognitive impairment and neurodegeneration with features in common with AD.([19-23]) In AD, deficits in brain insulin/IGF signalling are due to combined effects of insulin/IGF resistance and deficiency.”
BackgroundDiabetes and Alzheimer’s disease crosstalk
Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., & LaFerla, F. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.005 · Cited by 256
Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.001 · Cited by 212
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Agrawal, R., Mishra, B., Tyagi, E., Nath, C., & Shukla, R. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.008 · Cited by 133
Streptozotocin-induced sporadic Alzheimer’s disease: Selection of appropriate dose
Mehla, J., Pahuja, M., & Gupta, Y. K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120958 · Cited by 113
“In a previous study, it was reported that single (day 1) and thrice (day 1, 3, and 21) injections of STZ at the dose of 1 mg/kg caused impairment of learning and memory [12].”
Nasiri, E., Sankowski, R., Dietrich, H., Oikonomidi, A., Huerta, P. T., Popp, J., Al-Abed, Y., & Bacher, M. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00163-5 · Cited by 91
Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasiński, A., & Grieb, P. (2010) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-211-98811-4_32 · Cited by 79
“In a rat icv STZ dose of 1–3 mg/kg body weight is devoid of peripheral effects but produces a range of central effects including, inter alia, a decrease in brain glucose utilization, increased release of lactate from the brain, decrease of the level of ATP and phosphocreatine in brain tissues, and disturbances in lear…”
BackgroundIsik, A. T., Celik, T., Ulusoy, G., Ongoru, O., Elibol, B., Doruk, H., Bozoglu, E., Kayir, H., Mas, M. R., & Akman, S. (2009) · AGE · doi:10.1007/s11357-008-9078-8 · Cited by 76
Li, S.-Q., Yu, Y., Han, J.-Z., Wang, D., Liu, J., Qian, F., Fan, G.-H., Bucala, R., & Ye, R. D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0396-3 · Cited by 59
“lished studies that compared the ICV-STZ approach with other mouse models of AD [24, 34].”
MethodResult(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
Diabetes type II: A risk factor for depression-Parkinson–Alzheimer?
Riederer, P., Bartl, J., Laux, G., & Grünblatt, E. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9203-1 · Cited by 51
Zhang, Y., Yin, F., Liu, J., & Liu, Z. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12673 · Cited by 34
Zimmer, E. R., Leuzy, A., Bhat, V., Gauthier, S., & Rosa-Neto, P. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-6 · Cited by 30
“In contrast, genetic models lacking human tau expression such as p25-transgenic mice, which overexpress the human activator of CDK5 kinase, [23,24] and chemical-induced models [25,26] lead to hyperphosphorylated tau in brain regions rich in tau expression, but not to NFT formation (for review of tau rodent models see…”
BackgroundMehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29
Sweet Mitochondria: A Shortcut to Alzheimer’s Disease
Moreira, P. I. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170931 · Cited by 20
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Metadata
- Authors
- Grünblatt, E., Salkovic‐Petrisic, M., Osmanovic, J., Riederer, P., & Hoyer, S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-12
- Volume
- 101
- Issue
- 3
- Pages
- 757-770
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1500350553
- Cited by
- 374
- References
- 83
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.